Protagonist Therapeutics (PTGX) Interest Expenses (2015 - 2025)

Protagonist Therapeutics (PTGX) has 11 years of Interest Expenses data on file, last reported at $501.3 million in Q4 2025.

• For the quarter ending Q4 2025, Interest Expenses rose 59507.61% year-over-year to $501.3 million; the trailing twelve-month figure through Dec 2025 stood at $501.3 million (up 85886.28% YoY), and the FY2025 full-year result was $501.3 million, up 227.86% from the prior year.
• Interest Expenses climbed to $501.3 million in Q4 2025, from $841000.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $501.3 million in Q4 2025 to a low of -$1.6 million in Q4 2023.
• A 5-year average of $57.6 million and a median of $2.1 million in 2024 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses slumped 344.0% in 2023 and soared 59507.61% in 2025, its largest moves.
• Tracing PTGX's Interest Expenses over 5 years: stood at $556000.0 in 2021, then grew by 21.4% to $675000.0 in 2022, then sank by 344.0% to -$1.6 million in 2023, then soared by 151.06% to $841000.0 in 2024, then soared by 59507.61% to $501.3 million in 2025.
• Business Quant data shows PTGX's Interest Expenses at $501.3 million in Q4 2025, $841000.0 in Q4 2024, and $1.9 million in Q3 2024.